NAD+ Tirzepatide Stack: Biomarkers & Provider Guidance

Last reviewed: May 15, 2026

Last updated: May 15, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

NAD+ and tirzepatide combination protocols are emerging in some wellness practices, but clinical evidence for their combined use remains limited and largely anecdotal. Tirzepatide, a GIP/GLP-1 receptor agonist, works through established appetite and metabolic pathways, while NAD+ supplementation targets cellular energy metabolism.

Before considering any combination therapy, patients benefit from understanding their individual metabolic profile, genetic predispositions, and mitochondrial health markers. PlexusDx supports precision conversations between patients and providers by clarifying these baseline factors, ensuring safer, more personalized decision-making.

What NAD+ Does in Cellular Metabolism

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme essential for energy production in mitochondria. It plays a role in sirtuins, proteins linked to cellular stress resilience and aging processes. NAD+ levels naturally decline with age, and supplementation is proposed to restore cellular energy capacity and metabolic efficiency.

When combined with tirzepatide, proponents suggest NAD+ may amplify metabolic benefits by improving mitochondrial function. However, direct clinical evidence of this synergistic effect in humans remains sparse. Most studies examining NAD+ focus on aging, neurodegeneration, or metabolic disease independently, not in combination with GLP-1 drugs.

Biomarkers That Inform Stack Suitability

Before pursuing NAD+ and tirzepatide together, several biomarkers should be evaluated to assess baseline metabolic and mitochondrial health. These markers help providers determine if combination therapy aligns with individual physiology and whether monitoring is appropriate.

Biomarker	Clinical Relevance to NAD+ + Tirzepatide Stack
NAD+/NADH Ratio	Reflects cellular redox state; baseline measurement helps determine NAD+ supplementation need and response trajectory.
Lactate & Pyruvate Levels	Indicate mitochondrial efficiency; imbalances suggest compromised cellular energy metabolism where NAD+ may be considered.
Fasting Insulin & HOMA-IR	Assess insulin resistance; tirzepatide targets this directly, while NAD+ may support metabolic substrate utilization.
Adiponectin & Inflammatory Markers	Reflect metabolic health; both tirzepatide and cellular energy optimization affect inflammation and insulin sensitivity.
Liver & Kidney Function Tests	Essential safety baseline; both NAD+ metabolism and tirzepatide clearance depend on hepatic and renal function.

Genetic Predispositions in Metabolic Pathways

Individual genetic variants influence how efficiently a person metabolizes glucose, uses mitochondrial energy, and responds to GLP-1 receptor signaling. Understanding these predispositions can help patients and providers determine whether NAD+ addition offers genuine value or creates unnecessary complexity.

PlexusDx Precision Peptide Genetic Test identifies variants in GLP1R, GIPR, FTO, and MC4R pathways. These reveal predispositions in appetite regulation and metabolic efficiency—key factors when evaluating whether tirzepatide alone is sufficient or whether mitochondrial support via NAD+ could provide context-specific benefit.

Safety Considerations and Provider Oversight

Combining NAD+ with tirzepatide introduces unknown interaction risks. Tirzepatide slows gastric motility and can affect absorption of oral supplements, including NAD+ precursors. Neither FDA-approved nor compounded tirzepatide studies include NAD+ co-supplementation, so adverse event data is absent. Close provider monitoring is mandatory.

Patients should only pursue this approach under direct medical supervision with baseline and ongoing biomarker monitoring. Providers must assess renal and hepatic function, monitor for unexpected gastrointestinal or metabolic side effects, and have clear criteria for discontinuation. Self-directed stacking without professional guidance carries unquantified risk.

How PlexusDx Supports a More Personalized Approach

PlexusDx genetic testing may help provide context into your baseline metabolic efficiency and GLP-1 pathway predispositions. Variants in GLP1R, GIPR, FTO, and MC4R can reveal whether your genetic profile suggests strong tirzepatide responsiveness or metabolic challenges that might warrant additional interventions like NAD+ support. This information should be interpreted with a qualified healthcare provider.

The Precision Peptide Genetic Test identifies predispositions in peptide and metabolic pathways, not exact medication response. Understanding these genetic factors can support a more informed conversation with your provider about whether combination therapies like NAD+ and tirzepatide align with your individual physiology. Genetic predisposition is one factor among many—biomarkers, clinical history, and provider judgment are equally important.

If you are considering compounded tirzepatide or exploring combination protocols, PlexusDx recommends discussing genetic testing and biomarker evaluation with your healthcare provider first. These insights help create a shared evidence-based foundation for safer, more personalized treatment decisions.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $279/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the most affordable GLP-1 option for nad+ tirzepatide stack: biomarkers & pro?

PlexusDx offers compounded semaglutide starting at $149/mo and a Microdose GLP-1 Protocol from $129/month — both from licensed 503A compounding pharmacies, with no membership fee.

Does PlexusDx serve patients in all 50 states?

Yes. PlexusDx serves all 50 states. Five states require a scheduled live video consultation before the first prescription is issued; all others use async intake.

How does genetic testing improve GLP-1 outcomes?

Variants like GIPR rs1800437 affect GIP receptor function and predict differential response to tirzepatide versus semaglutide. PlexusDx's Precision Peptide Genetic Test evaluates 150+ relevant variants to guide medication selection.

Is compounded semaglutide the same as Wegovy or Ozempic?

Compounded semaglutide uses the same active ingredient but is not FDA-approved. It is prepared under federal compounding regulations at licensed 503A compounding pharmacies.

Can I use HSA or FSA funds to pay for PlexusDx?

Yes. Prescription GLP-1 medications from PlexusDx are HSA/FSA eligible with a valid prescription. PlexusDx accepts HSA and FSA cards directly at checkout.